In its annual report analyzing the biopharmaceutical sector’s rate of return on innovation, Deloitte says the industry is expected to continue seeing increasing ROI, but that continuing on that positive path will require companies to be “brave and bold.” It describes such an approach as one that pursues originality, such as novel mechanisms of action and unmet medical needs, rather than trying to do what has worked well for competitors.
Key Takeaways
- Deloitte found that the 20 pharma companies with the highest R&D spend increased internal return on investment for the second straight year.
In the 15th edition of its Measuring the return from pharmaceutical innovation report, released on 25 March, Deloitte said the...
Welcome to Scrip
Create an account to read this article
Already a subscriber?
